These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6329121)

  • 1. The effects of ceruletide in schizophrenia.
    Hommer DW; Pickar D; Roy A; Ninan P; Boronow J; Paul SM
    Arch Gen Psychiatry; 1984 Jun; 41(6):617-9. PubMed ID: 6329121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of cholecystokinin-like peptides in schizophrenics and normal human subjects.
    Hommer DW; Pickar D; Crawley JN; Weingartner H; Paul SM
    Ann N Y Acad Sci; 1985; 448():542-52. PubMed ID: 3896099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind study with ceruletide in chronic schizophrenic patients: biochemical and clinical results.
    Albus M; von Gellhorn K; Münch U; Naber D; Ackenheil M
    Psychiatry Res; 1986 Sep; 19(1):1-7. PubMed ID: 3538106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceruletide for schizophrenia: a double-blind study.
    Mattes JA; Hom W; Rochford JM; Orlosky M
    Biol Psychiatry; 1985 May; 20(5):533-8. PubMed ID: 2859054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high-dose, double-blind study of ceruletide in the treatment of schizophrenia.
    Mattes JA; Hom W; Rochford JM
    Am J Psychiatry; 1985 Dec; 142(12):1482-4. PubMed ID: 3907376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic effects of caerulein, a decapeptide chemically related to cholecystokinin octapeptide, on schizophrenia.
    Moroji T; Watanabe N; Aoki N; Itoh S
    Int Pharmacopsychiatry; 1982; 17(4):255-73. PubMed ID: 7185770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study on the antipsychotic properties of desenkephalin-gamma-endorphin and ceruletide in schizophrenic patients.
    Verhoeven WM; Westenberg HG; van Ree JM
    Acta Psychiatr Scand; 1986 Apr; 73(4):372-82. PubMed ID: 3524119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study.
    Kojima T; Yamauchi T; Miyasaka M; Koshino Y; Nakane Y; Takahashi R; Shimazono Y; Yagi G
    Psychiatry Res; 1992 Aug; 43(2):129-36. PubMed ID: 1357701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceruletide resembles antipsychotics in rats and schizophrenic patients. Preliminary report.
    van Ree JM; Verhoeven WM; Brouwer GJ; de Wied D
    Neuropsychobiology; 1984; 12(1):4-8. PubMed ID: 6151145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic effects of ceruletide (caerulein) on chronic schizophrenia.
    Moroji T; Watanabe N; Aoki N; Itoh S
    Arch Gen Psychiatry; 1982 Apr; 39(4):485-6. PubMed ID: 7039550
    [No Abstract]   [Full Text] [Related]  

  • 11. Antipsychotic effects of ceruletide in chronic schizophrenia. An appraisal of the long-term, intermittent medication of ceruletide in chronic schizophrenia.
    Moroji T; Itoh K; Itoh K
    Ann N Y Acad Sci; 1985; 448():518-34. PubMed ID: 3927809
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of ceruletide on clinical symptoms and EEGS in schizophrenia.
    Mizuki Y; Ushijima I; Habu K; Nakamura K; Yamada M
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(4):511-22. PubMed ID: 3406428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceruletide: a new drug for the treatment of schizophrenic patients?
    Albus M; Ackenheil M; Münch U; Naber D
    Arch Gen Psychiatry; 1984 May; 41(5):528. PubMed ID: 6372739
    [No Abstract]   [Full Text] [Related]  

  • 14. Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia.
    Peselow E; Angrist B; Sudilovsky A; Corwin J; Siekierski J; Trent F; Rotrosen J
    Psychopharmacology (Berl); 1987; 91(1):80-4. PubMed ID: 2881320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced cholecystokinin levels in cerebrospinal fluid of parkinsonian and schizophrenic patients. Effect of ceruletide in schizophrenia.
    Lotstra F; Verbanck PM; Gilles C; Mendlewicz J; Vanderhaeghen JJ
    Ann N Y Acad Sci; 1985; 448():507-17. PubMed ID: 3896098
    [No Abstract]   [Full Text] [Related]  

  • 16. Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study.
    Nair NP; Bloom DM; Debonnel G; Schwartz G; Mosticyan S
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(4-6):711-4. PubMed ID: 6152344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
    Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM
    J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroleptic responsivity of negative and positive symptoms in schizophrenia.
    Breier A; Wolkowitz OM; Doran AR; Roy A; Boronow J; Hommer DW; Pickar D
    Am J Psychiatry; 1987 Dec; 144(12):1549-55. PubMed ID: 3688278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies.
    Tamminga CA; Littman RL; Alphs LD; Chase TN; Thaker GK; Wagman AM
    Psychopharmacology (Berl); 1986; 88(3):387-91. PubMed ID: 3083460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is cholecystokinin therapeutic in chronic schizophrenia?
    Boza RA; Rotondo DJ
    J Clin Psychiatry; 1985 Nov; 46(11):485-6. PubMed ID: 3902807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.